A Double-Masked, Placebo-Controlled Study of Fluoxetine for Hypochondriasis
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
This study assessed the efficacy, durability, and tolerability of fluoxetine for hypochondriasis, a disorder for which controlled pharmacological trials are scarce. Fifty-seven patients with hypochondriasis were enrolled: 12 discontinued during the placebo run-in, and 45 were randomized to either fluoxetine or placebo for 12 weeks (acute treatment). Responder status was defined as a Clinical Global Impression rating for hypochondriasis of much or very much improved. Secondary outcome measures included severity of hypochondriasis, somatization, anxiety, and depression. Responders to acute treatment entered a 12-week maintenance phase to week 24. Sustained responders at week 24 entered a 12-week double-masked discontinuation phase. Primary analysis used the intent-to-treat sample. More patients responded with improvement in hypochondriasis when given fluoxetine compared with placebo, starting at week 8 (50.0% vs 19.0%, P = 0.03) and continuing to week 12 (62.5% vs 33.3%, P = 0.05). Mean dose at week 12 dose was 51.4 mg (SD, +/-23 mg). The acute treatment response was maintained to week 24 with more responders in the fluoxetine compared with the placebo group (54.2% vs 23.8%, P = 0.04). Significant improvement was not noted on the continuous secondary outcomes measures of hypochondriasis, with the exception of the Clinical Global Impression hypochondriasis severity scale at week 24. Likelihood of response was not associated with severity of psychiatric comorbidity. Durability of response after controlled drug discontinuation could not be reasonably assessed, given the small sample size of patients who entered the discontinuation phase (n = 10). Fluoxetine was well tolerated, with no significant differences in discontinuation due to side effects between treatment groups. Fluoxetine is a moderately effective and well-tolerated treatment for hypochondriasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Pharmacotherapy studies are lacking, but two studies into treatments for Hypochondriasis support the use of Fluoxetine in combination with CBT, or alone [86, 87], and another earlier study found Paroxetine yielded similar effectiveness to CBT for hypochondriasis [88].”
From Illness Anxiety Disorder: A Review of the Current Research and Future Directions (2024) · cites this paper as [87]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These studies used scales of relevance to CYB such as the Y-BOCS modified for hypochondriasis [116,117].”
From Is cyberchondria a new transdiagnostic digital compulsive syndrome? A systematic review of the evidence (2020) · cites this paper as [117]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455 · cited 1×
“Other psychopathology was assessed by the Somatic Symptom Inventory (SSI),15,16 Beck Depression Inventory (BDI),(17) the Hamilton Depression Scale (HAM-D) (24 items),(18) and the Hamilton Anxiety Scale (HAM-A).(19)”
MethodThe Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110048007 · Cited by 7,712
Pilowsky, I. (1967) · British Journal of Psychiatry · doi:10.1192/bjp.113.494.89 · Cited by 865 · cited 2×
“Other hypochondriasis-specific assessments included the IEadministered measures (the Heightened Illness Concern [HIC] Severity Scale(11) and the Columbia Heightened Illness Concern–Obsessive-Compulsive Scale [CHIC-OCS]), a hypochondriasis-focused adaptation of the well-standardized Yale-Brown Obsessive Compulsive Scal…”
MethodCognitive Behavior Therapy for Hypochondriasis: A Randomized Controlled Trial
Barsky, A. J., & Ahern, D. K. (2004) · JAMA · doi:10.1001/jama.291.12.1464 · Cited by 307 · cited 1×
“These studies indicate that cognitive behavioral therapy can be helpful for patients with hypochondriasis.(7,8) However, there has been only 1 prior placebo-controlled pharmacotherapy study(9); this study demonstrated the short-term effectiveness of paroxetine, a selective serotonin reuptake inhibitor (SSRI), for the…”
BackgroundTwo psychological treatments for hypochondriasis: A randomised controlled trial
Clark, D. M., Salkovskis, P. M., Hackmann, A., Wells, A., Fennell, M., Ludgate, J., Ahmad, S., Richards, H. C., & Gelder, M. (1998) · British Journal of Psychiatry · doi:10.1192/bjp.173.3.218 · Cited by 270 · cited 1×
“These studies indicate that cognitive behavioral therapy can be helpful for patients with hypochondriasis.(7,8) However, there has been only 1 prior placebo-controlled pharmacotherapy study(9); this study demonstrated the short-term effectiveness of paroxetine, a selective serotonin reuptake inhibitor (SSRI), for the…”
BackgroundLin, E. H. B., Katon, W., Von Korff, M., Bush, T., Lipscomb, P., Russo, J., & Wagner, E. (1991) · Journal of General Internal Medicine · doi:10.1007/bf02598969 · Cited by 208 · cited 1×
“These patients respond poorly to standard medical management, often receive unnecessary tests or medical care, and are perceived by physicians as reluctant to accept a psychotherapy referral.(5,6) Despite its prevalence and adverse personal and public health impact, hypochondriasis has only recently been the subject o…”
BackgroundGreeven, A., van Balkom, A. J. L. M., Visser, S., Merkelbach, J. W., van Rood, Y. R., van Dyck, R., Van der Does, A. J. W., Zitman, F. G., & Spinhoven, P. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.1.91 · Cited by 183
Weinstein, M. C., Berwick, D. M., Goldman, P. A., Murphy, J. M., & Barsky, A. J. (1989) · Medical Care · doi:10.1097/00005650-198906000-00003 · Cited by 157
The prevalence of hypochondriasis in medical outpatients
BARSKY, A. J., Wyshak, G., Klerman, G. L., & Latham, K. S. (1990) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/bf00794988 · Cited by 142
Cited by
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
“…is not normally acceptable to patients, as those with marked health anxiety are typically very sensitive to adverse effects of medication: but fluoxetine showed some benefit over placebo, though this was not pronounced and occurred late in treatment (8–12 weeks [I (PCT)] (Fallon et al., 2008).”
BackgroundShould an obsessive-compulsive spectrum grouping of disorders be included in DSM-V?
Phillips, K. A., Stein, D. J., Rauch, S. L., Hollander, E., Fallon, B. A., Barsky, A., Fineberg, N., Mataix-Cols, D., Ferrão, Y. A., Saxena, S., et al. (2010) · Depression and Anxiety · doi:10.1002/da.20705 · Cited by 347
“Although no study has directly compared the relative responsiveness to treatment of patients with HYP versus SD, there are controlled studies using either CBT or SSRI therapy among patients with HYP that suggest that improvement is substantially greater on measures of health anxiety than on measures of somatization.([…”
BackgroundResultSelf-citationVismara, M., Caricasole, V., Starcevic, V., Cinosi, E., Dell'Osso, B., Martinotti, G., & Fineberg, N. A. (2020) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2020.152167 · Cited by 224
Illness Anxiety Disorder: Psychopathology, Epidemiology, Clinical Characteristics, and Treatment.
Scarella, T. M., Boland, R. J., & Barsky, A. J. (2019) · Psychosomatic Medicine · doi:10.1097/psy.0000000000000691 · Cited by 102
Recent Advances in the Understanding and Treatment of Health Anxiety.
Tyrer, P. (2018) · Current Psychiatry Reports · doi:10.1007/s11920-018-0912-0 · Cited by 102
Metadata
- Authors
- Fallon, B. A., Petkova, E., Skritskaya, N., Sanchez-Lacay, A., Schneier, F., Vermes, D., Cheng, J., & Liebowitz, M. R.
- Affiliations
- New York State Psychiatric Institute (US)
- Corresponding author
- Fallon, Brian A.
- Skritskaya, Natalia
- Schneier, Franklin
- Vermes, Donna
- Liebowitz, Michael R.
- ORCID
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2008-12
- Volume
- 28
- Issue
- 6
- Pages
- 638-645
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2026930104
- Cited by
- 63
- References
- 20
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 2 · 2021: 1 · 2020: 3 · 2019: 4 · 2018: 4 · 2017: 4 · 2016: 3 · 2015: 5 · 2014: 7 · 2013: 5 · 2012: 4
- FWCI
- 2.80
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Columbia Academic Commons (Columbia University)
- Funders
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- National Institute of Mental Health (R29MH049409, R29 MH49409)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Psychosomatic Disorders and Their Treatments
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Health Sciences › Medicine › Psychiatry and Mental health › Fibromyalgia and Chronic Fatigue Syndrome Research
- Keywords
- fluoxetine, health anxiety, somatic symptom disorder, SSRI antidepressants, treatment efficacy, maintenance therapy, drug discontinuation, somatization, anxiety, depression, psychiatric comorbidity, tolerability
- MeSH terms
- Adult, Aged, Connecticut, Dose-Response Relationship, Drug, Double-Blind Method, Female, Fluoxetine, Humans, Hypochondriasis, Male, Middle Aged, New York, Patient Dropouts, Psychiatric Status Rating Scales, Severity of Illness Index, Time Factors, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Double-Masked, Placebo-Controlled Study of Fluoxetine for Hypochondriasis. https://app.cochat.ai/papers/10.1097/jcp.0b013e31818d21cf
- The paper
- Fallon, B. A., Petkova, E., Skritskaya, N., Sanchez-Lacay, A., Schneier, F., Vermes, D., Cheng, J., & Liebowitz, M. R. (2008). A Double-Masked, Placebo-Controlled Study of Fluoxetine for Hypochondriasis. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e31818d21cf
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.